Trial Profile
A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2019
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Metformin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MAXIM
- 16 Jun 2019 Status changed from recruiting to completed.
- 16 Nov 2011 New trial record